Reading Time: 2 minutesIntroduction Growth hormone deficiency (GHD) affects approximately 1 in 3,500 to 10,000 individuals in the United States, with adult males comprising a significant subset due to idiopathic or acquired etiologies such as pituitary adenomas or traumatic brain injury. Nutropin (somatropin), a recombinant human growth hormone (rhGH), has emerged as a cornerstone therapy for restoring physiological GH levels, promoting linear growth, metabolic homeostasis, and tissue repair. However, emerging evidence suggests nuanced impacts on oral health, particularly in American males aged 18-65, where socioeconomic factors, dietary habits, and access to dental care intersect with endocrine management. This article synthesizes clinical data, radiographic … Continue reading →